TY - JOUR
T1 - Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease
AU - Fujieda, Yuichiro
AU - Doi, Mototsugu
AU - Asaka, Takuya
AU - Ota, Masahiro
AU - Hisada, Ryo
AU - Ohnishi, Naoki
AU - Kono, Michihiro
AU - Kameda, Hiraku
AU - Nakazawa, Daigo
AU - Kato, Masaru
AU - Amengual, Olga
AU - Takahata, Masahiko
AU - Yasuda, Shinsuke
AU - Kitagawa, Yoshimasa
AU - Atsumi, Tatsuya
N1 - Publisher Copyright:
© 2020, The Japanese Society Bone and Mineral Research and Springer Japan KK, part of Springer Nature.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Introduction: Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is a rare but serious complication in patients receiving antiresorprtive agents (AR). However, the incidence of ARONJ after tooth extraction in patients with autoimmune disease (AID) remains unclear. The present study aimed to clarify the high-risk population of ARONJ in patients with AID. Materials and methods: The study population comprised 232 patients treated with AR, AID or non-AID, who had undergone dental extraction from January 2011 to September 2017. The incidence and risk factors of ARONJ were analysed retrospectively. Additionally, the relationship between ARONJ and osteoporotic fracture (OF) and AR discontinuation during dental procedures was investigated. Results: Of 232 patients, 10 developed ARONJ within 1 year of dental extraction. The incidence of ARONJ in patients with AID was higher than that in non-AID patients (2.0/100 person-year vs 0.5/100 person-year; p = 0.03). Among the AID patients, RA patients had strikingly high incidence of ARONJ (3.6/100 person-year). The incidence of neither ARONJ nor OF significantly differed between patients who continued and discontinued AR in the perioperative period. Conclusion: Patients with AID who undergo dental extraction are at high risk of ARONJ. Discontinuation of AR would not significantly contribute to reduce the incidence of ARONJ in those patients.
AB - Introduction: Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is a rare but serious complication in patients receiving antiresorprtive agents (AR). However, the incidence of ARONJ after tooth extraction in patients with autoimmune disease (AID) remains unclear. The present study aimed to clarify the high-risk population of ARONJ in patients with AID. Materials and methods: The study population comprised 232 patients treated with AR, AID or non-AID, who had undergone dental extraction from January 2011 to September 2017. The incidence and risk factors of ARONJ were analysed retrospectively. Additionally, the relationship between ARONJ and osteoporotic fracture (OF) and AR discontinuation during dental procedures was investigated. Results: Of 232 patients, 10 developed ARONJ within 1 year of dental extraction. The incidence of ARONJ in patients with AID was higher than that in non-AID patients (2.0/100 person-year vs 0.5/100 person-year; p = 0.03). Among the AID patients, RA patients had strikingly high incidence of ARONJ (3.6/100 person-year). The incidence of neither ARONJ nor OF significantly differed between patients who continued and discontinued AR in the perioperative period. Conclusion: Patients with AID who undergo dental extraction are at high risk of ARONJ. Discontinuation of AR would not significantly contribute to reduce the incidence of ARONJ in those patients.
KW - Antiresorptive agents-related osteonecrosis of the jaw
KW - Autoimmune disease
KW - Osteoporosis
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85079624386&partnerID=8YFLogxK
U2 - 10.1007/s00774-020-01089-y
DO - 10.1007/s00774-020-01089-y
M3 - 学術論文
C2 - 32076874
AN - SCOPUS:85079624386
SN - 0914-8779
VL - 38
SP - 581
EP - 588
JO - Journal of Bone and Mineral Metabolism
JF - Journal of Bone and Mineral Metabolism
IS - 4
ER -
